Triteq have worked with Zilico Ltd, a spin-out company from Sheffield Teaching Hospitals NHS Foundation Trust and the University of Sheffield, from the initial concept stage of Zedscan 1, a ground breaking cervical cancer diagnostic device. So we were delighted to hear that ZedScan Ihas obtained approval from Therapeutic Goods Administration (TGA) – the regulatory body for therapeutic goods (including medicines, medical devices, gene technology, and blood products) in Australia. TGA approval for ZedScan means that is now listed on the register of medical devices and can be sold to the Australian Market.
TGA approval is also accepted by other countries including Singapore and is viewed positively by regulatory authorities where there is a Mutual Recognition Agreement in place such as New Zealand.
The system which has already received EC certification from its notified body, offers more accurate detection of cervical neoplasia in real-time, enabling clinicians to improve patient management. The ZedScan I system is used alongside colposcopy on women identified with an abnormal smear result. ZedScan offers clinical benefits by identifying those patients who require treatment at first visit, facilitating a wider use of “Select & Treat in addition to reducing the number of cervical biopsies performed on each patient by pin-pointing the optimum site for biopsy . Zilico’s patented Electrical Impedance Spectroscopy (EIS) technology exploits the different electrical resistivity of normal, pre-cancerous and cancerous tissue.
In April this year, Zilico won the ‘Partnership with the NHS Award’ at the Medilink UK Healthcare Business Awards, a national event which was held at the end of the first day of the Med-Tech Innovation Expo, at the Ricoh Arena, Coventry. Sameer Kothari, Chief Executive of Zilico Ltd, said: “This award is also deserved recognition for the significant body of work that has gone in to the development of ZedScan from a number of expert partners and we are delighted for everyone who has been involved.”